Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Moderna wins reprieve in COVID-19 vaccine dispute
Americas
Alnylam backed down after judge’s patent interpretation favoured Moderna | Case is part of a spate of infringement lawsuits aimed at both Moderna and Pfizer | Plaintiff may be allowed to refile in future.   3 October 2024
Polsinelli grows roster with ex-corporate counsel
Careers
Prior to his new role, the senior hire spent eight years as an in-house counsel at a major pharma company.   19 September 2024
WBD to merge with firm to create ‘powerhouse’ practice
Careers
Deal marks the third major M&A to be announced so far this month | Combined firms have a total gross revenue of more than $742 million | Business marriage seen as “natural fit and clear win-win”.   12 September 2024
Unified Patent Court
A vocal advocate of greater UPC transparency, Freshfields’ Christopher Stothers shares his views on the court’s journey so far, and why it is still so exciting.   12 September 2024
Unified Patent Court
UPC clarifies that evidence must show that pre-launch preparations are complete for threat of imminent infringement to occur | Question remains over how the UPC will deal with the cumulative activities of several companies in a group | Court also broaches key cross-border question.   9 September 2024
Europe
Preliminary injunction doesn't extend to Ireland because it has not ratified UPC Treaty | Case concerns dispute over patents covering continuous glucose monitoring devices used in the management of diabetes | Injunction in favour of the US market leader now applies to three markets rather than four.   20 August 2024
Americas
AstraZeneca successfully argued that “no reasonable jury” could find it had infringed the patents-in-suit claiming lung cancer patents | Reprieve comes after misconduct allegations against a Pfizer unit fell flat earlier this month.   15 August 2024
Americas
Litigator brings extensive courtroom experience and advises clients on how to navigate disputes through federal courts, state courts, and arbitrations.   13 August 2024
Americas
Swiss biopharma took preemptive legal action against US rival after learning it would be subject to “aggressive” enforcement over therapy | Technology at heart of case treats disruptions to healthy bacterial organisms in human intestinal tract.   13 August 2024
Americas
A Delaware jury found AstraZeneca liable for induced infringement of a cancer treatment in May | Pharma company levelled allegations of "unclean hands" and "patent misuse" at Pfizer unit.   8 August 2024

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.